Celon PharmaWAR:CLN -0.10%57 Quick Ratio is 0.75 as of Mar. 2026, which is 67% below its 10-year median of 2.27. GuruFocus rates WAR:CLN with a GF Score™ of 57/100 and a GF Value™ of zł22.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 994 Drug Manufacturers companies, Celon Pharma ranks worse than 78.37% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Celon Pharma's quick ratio for the quarter that ended in Mar. 2026 was 0.75.
Celon Pharma has a quick ratio of 0.75. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Celon Pharma's Quick Ratio or its related term are showing as below:
WAR:CLN'
s Quick Ratio Range Over the Past 10 Years
Min: 0.4 Med: 2.27 Max: 17.57
Current: 0.75
During the past 11 years, Celon Pharma's highest Quick Ratio was 17.57. The lowest was 0.40. And the median was 2.27.
WAR:CLN's Quick Ratio is ranked worse than 78.37% of 994
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs WAR:CLN: 0.75
Celon Pharma (WAR:CLN) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Celon Pharma Quick Ratio Related Terms
Celon Pharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for Celon Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CLN vs ZTS, UTHR, VTRS: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Celon Pharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Celon Pharma's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celon Pharma (WAR:CLN) has a Quick Ratio of 0.75 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Celon Pharma and its competitors. This is 67% below median its historical median of 2.27. Over the past decade, Celon Pharma's Quick Ratio has ranged from 0.40 to 17.57. According to the industry distribution chart, Celon Pharma ranks #779 out of 994 companies in the Drug Manufacturers industry, placing it in the top 78.4%.
Is Celon Pharma's Quick Ratio too high?
Celon Pharma's current Quick Ratio of 0.75 is 67% below median its 10-year median of 2.27. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 17.57. The Drug Manufacturers industry median Quick Ratio is 1.45. Celon Pharma's value of 0.75 is 48.3% below this industry median. Based on the distribution chart, Celon Pharma ranks #779 out of 994 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Celon Pharma has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #779 out of 994 companies for Quick Ratio. This places Celon Pharma in the lower half of its industry. The industry median Quick Ratio is 1.45. Celon Pharma's value of 0.75 is 48.3% below this benchmark. Historically, Celon Pharma's own Quick Ratio has ranged from 0.40 to 17.57 over the past decade. While the company's 10-year median is 2.27 vs. the industry median of 1.45, Celon Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current Quick Ratio of 0.75 is 48.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current Quick Ratio is 0.75, which is 67% below median its own 10-year median of 2.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł22.61, compared to a current price of zł19.84 — trading 12.3% below its estimated fair value. The current Quick Ratio is 0.75, which is 67% below median its 10-year median of 2.27 and 48.3% below the Drug Manufacturers industry median of 1.45. Celon Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Quick Ratio is 0.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (WAR:CLN) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of zł19.84 is trading 12.3% below its estimated GF Value™ of zł22.61.
GuruFocus considers Celon Pharma to be Modestly Undervalued.
Key valuation signals for WAR:CLN:
Quick Ratio: 0.75 (67% below median its 10-year median of 2.27)
GF Value™: zł22.61 vs. price of zł19.84 (12.3% below fair value)
Industry Position: 48.3% below the Drug Manufacturers median (#779 of 994)
No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
57GF Score
Get the complete analysis for WAR:CLN
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CLN has been successfully added to your 
